BOLD vs RGT Comparison

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.